Meeting
2021 ASCO Annual Meeting
Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC).
Authors
Robert J. Motzer
Memorial Sloan Kettering Cancer Center, New York, NY
Robert J. Motzer , Toni K. Choueiri , Jessica May , Youngmin Kwon , Nifasha Rusibamayila , Marc Botteman , Melissa Hamilton , Flavia Ejzykowicz , David Cella
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Outcomes
Clinical Trial Registration Number
NCT02231749
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6568)
DOI
10.1200/JCO.2021.39.15_suppl.6568
Abstract #
6568
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
First Author: Nizar M. Tannir
Poster
2022 ASCO Genitourinary Cancers Symposium
Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.
First Author: Ajeet Gajra
Poster
2021 Genitourinary Cancers Symposium
Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
First Author: Nizar M. Tannir
Poster
2020 Genitourinary Cancers Symposium
Relative risk of pneumonitis associated with first-line use of immune checkpoint inhibitors in advanced renal cell carcinoma.
First Author: Nusrat Jahan